Skip to main content
. 2024 Feb 2;8(9):2094–2103. doi: 10.1182/bloodadvances.2023011980

Figure 3.

Figure 3.

Outcomes for patients with LAR ITDpos (≤0.4) vs HAR ITDpos (>0.4) according to cooccurring risk group. (A) 5-year EFS, (B) 5-year OS, (C) 5-year relapse risk from end of induction 1.